Estimating the potential cost-effectiveness of using Haemophilus influenzae type b (Hib) vaccine. Field test version 1
The objective of this document is to provide guidelines for estimating the potential cost-effectiveness of using Hib vaccine, from a health sector perspective. It includes guidelines for estimating two major categories of costs: 1) costs of vaccine and its administration, and 2) treatment costs averted as a result of immunization. This document is intended for use with the WHO document: Estimating the local burden of Haemophilus influenzae type b (Hib) disease preventable by vaccination: A rapid assessment tool (WHO/V&B/01.27). Although this document is focused on costs associated with the introduction of Hib vaccine, the same principles can be applied when evaluating the cost-effectiveness of other vaccines, e.g. HepB, as well. The audience for this document includes ministries of health and other technical agencies who are involved with the evaluation and introduction of new vaccines.
Size: 40 KB